High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Today Earnings (a.m.): Merck, Pfizer, McDonald's, Caterpillar, Spotify, Apollo, TPG, Marathon Petroleum, Archer-Daniels-Midland, DuPont, Kimberly-Clark Earnings (p.m.): SpaceX, Advanced Micro Devices, ...
CVS heads into Q2 earnings with estimates pointing to revenue and EPS growth as Aetna initiatives and key business segments support results.
As employers drop coverage for GLP-1 drugs like Wegovy and Zepbound, retail giants are competing to lock in customers through direct-to-consumer programs
Recent earnings expectations and fresh store openings have put CVS Health (CVS) in focus for investors. The stock now sits near US$105 after a strong past year, raising questions about what is already reflected in the price. See our latest analysis for CVS Health. Over the past year, CVS Health has seen its share price move sharply higher, supported by a 90 day share price return of 28.18% and a 1 year total shareholder return of 74.81%. Recent store openings, product launches and...
Globus Medical will report Q2 results on Aug. 6. Investors will be keen to know whether Enabling Technologies and Spine strength aid revenue & earnings growth.
The lever behind UnitedHealth stock's climb was a Medicare Advantage repricing management had described months before the run began, and the hard part was believing a plan whose author had just been wrong.
According to the average brokerage recommendation (ABR), one should invest in CVS Health (CVS). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Beyond analysts' top-and-bottom-line estimates for CVS Health (CVS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.
The telehealth company is making a bold pivot that's driving growth, but the stock's recent slide has investors wondering if the price of admission is still too high.
Add another member to the fast-and-furious AI unicorn club: Simile
CRL is set to report Q2 results on Aug. 5 as investors watch segment demand, divestitures, and whether the company can extend its earnings beat streak.
Knorr-Bremse AG (KNRRY) achieves highest quarterly operating EBIT margin in five and a half years, while launching a 'Growth Beyond' strategy targeting EUR10 billion in revenue by 2030.
Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
X sued the WFA in 2024 for conducting what it called a "systematic illegal boycott" of the platform after it saw a decline in advertising revenue following Musk's $44 billion takeover of the social network
July 29 (Reuters) - SpaceX's X and the World Federation of Advertisers (WFA) said on Wednesday they had settled litigation over an alleged advertiser boycott of the social media platform linked to the
ZBH heads into Q2 earnings with expectations of modest revenue growth as investors watch demand trends across knees, hips and robotics.
CVS Health opened new pharmacy focused CVS Pharmacy locations in smaller, neighborhood formats across the United States. The company began offering the Kate Farms High Protein Nutrition Shake on shelves nationwide in CVS stores. These moves expand CVS Health's physical footprint and its presence in the wellness and nutrition category. CVS Health (NYSE: CVS) is adding fresh operational moves on top of a strong recent share price run. The stock trades at $109.34 and is up 36.5% year to date,...
CVS Health (CVS) closed the most recent trading day at $109.34, moving +2.12% from the previous trading session.
Administration officials told the Wall Street Journal that the subsidy program that has helped suppress Medicare Part D prescription drug plan premiums will not be renewed for 2027.
Humana reports earnings Wednesday after its stock surged this year on improving confidence in Medicare Advantage insurers. Investors will be watching medical costs and the company’s outlook.
HSIC heads into Q2 earnings with expectations for revenue and EPS growth as dental, specialty products and AI-enabled technology remain in focus.
CVS Health has rallied the broader market over the past year, and analysts remain highly optimistic about the stock’s prospects.
CVS, CAH, HUM and ACAD show favorable earnings indicators ahead of Q2 results as healthcare demand stays resilient despite margin pressures.
(Bloomberg) -- US companies that are integrating artificial intelligence capabilities are well positioned this earnings season as they’re poised for stronger profit margins, according to Morgan Stanley strategists.Most Read from BloombergDeepSeek Suspends Fundraising After Viral US-China PostsUS, Iran Extend Pause in Strikes as Oman Holds Hormuz TalksSpaceX at $100 Would Imply Zero AI Value, Morgan Stanley SaysChina Chipmaker CXMT Jumps 466% in Debut After Blockbuster IPOStocks, Bonds Rise in Re
They are riding strong tailwinds that could lift them higher.
The healthcare giant looks expensive on today's numbers, but a patient investor is effectively buying it at a significant discount to that price.
HCA tops Q2 EPS estimates on higher admissions and revenue per admission but trims parts of its 2026 guidance as higher expenses and weaker surgical volumes weigh on results.
Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
